You’ve probably seen one before. A genetic health report that says something like: “You carry a variant associated with increased risk of X.” No context. No sense of how strong the evidence is. No way to tell whether you should talk to your doctor or shrug it off.

This is the confidence problem. And it affects nearly every consumer genetic health report on the market.

The binary trap

Most direct-to-consumer (DTC) genetic testing companies treat findings as binary. You either carry a variant or you don’t. You’re either “at risk” or “typical.” Green checkmark or red flag.

That framing feels clean. It’s easy to design around. But it’s misleading, because it treats every genetic association as equally reliable. And they’re not. Not even close.

Some genetic variants (SNPs) have been studied in hundreds of thousands of people across dozens of populations, with molecular mechanisms we understand down to the protein level. Others come from a single genome-wide association study with modest sample sizes and no functional follow-up.

Presenting both with the same visual weight is like treating a peer-reviewed meta-analysis and a single preliminary study as equally trustworthy. You wouldn’t do that in medicine. You shouldn’t do it in genetics either.

Why different SNPs carry different evidence levels

When researchers identify a link between a genetic variant and a health trait, that finding goes through a long process of validation. Not every variant makes it through every stage. Here’s what separates strong evidence from weak:

Replication quality. Has the association been confirmed in independent studies, across different research groups and populations? A finding replicated in 100+ studies is fundamentally different from one seen in a single cohort.

Effect size. How much does carrying the variant actually change your risk? An odds ratio of 3.5 means carriers face roughly 3.5 times the risk compared to non-carriers. An odds ratio of 1.1 means a 10% increase. Both are statistically “significant,” but their real-world impact couldn’t be more different.

Functional mechanism. Do researchers understand why this variant matters at the molecular level? Can they explain the protein change, the pathway disruption, the downstream biological consequence? Variants with known mechanisms are far more reliable than statistical associations without a clear biological story.

Population scope. Has the association been validated across diverse populations, or only in one ethnic group? Some variants have dramatically different frequencies and effects depending on ancestry.

What confidence scoring actually means

Confidence scoring takes all of these factors and distills them into something actionable. Instead of treating every genetic finding as equally valid, each insight gets scored based on the strength of its underlying evidence.

At SoDNAscan, every SNP in our reference database carries three key data points:

Evidence tier: “established” (extensively validated, well-understood mechanism) or “emerging” (promising research, but less replication or unclear mechanism)
Confidence score: A value between 0 and 1 reflecting overall evidence quality, replication depth, and clinical validation
Effect size: The magnitude of the variant’s biological impact, expressed as an odds ratio or relative risk

These aren’t arbitrary labels. They’re derived from peer-reviewed sources including ClinVar, PharmGKB, CPIC clinical guidelines, and the GWAS Catalog.

The gap between strong and weak evidence, in real numbers

Let’s look at actual examples from our database to see why this matters.

High-confidence findings

rs6025 (Factor V Leiden, F5 gene) Confidence: 0.97 | Effect size: 3.5 | Tier: Established

This variant is one of the most thoroughly studied in human genetics. It causes a specific amino acid change (Arg506Gln) that makes Factor V resistant to activated protein C, leading to hypercoagulability. Carriers face 3 to 7 times the normal risk of venous thromboembolism. ClinVar classifies it as pathogenic, and extensive meta-analyses confirm the association. About 5% of Europeans carry it. If your report flags this variant, that’s a finding worth discussing with your healthcare provider.

rs4149056 (SLCO1B1 gene) Confidence: 0.95 | Effect size: 4.5 | Tier: Established

If you take statins, this one matters. It reduces hepatic uptake of statins, increasing systemic exposure and the risk of statin-induced myopathy. CPIC clinical guidelines specifically recommend reduced simvastatin doses for carriers. PharmGKB rates the evidence at Level 1A, the highest tier.

rs334 (Sickle cell variant, HBB gene) Confidence: 0.99 | Effect size: 10.0 | Tier: Established

The highest confidence score in our entire database. The molecular mechanism is crystal clear: a single amino acid change causes hemoglobin to polymerize under low oxygen conditions. This is genetics at its most definitive.

Mid-range findings

rs6265 (BDNF gene) Confidence: 0.88 | Effect size: 1.4 | Tier: Established

The Val66Met variant affects neuroplasticity and has been associated with reduced hippocampal volume and altered memory. The evidence is real, but the effect size is modest and the outcomes interact heavily with environmental factors like stress exposure. Worth knowing about, but not a single-variable explanation for anything.

rs1805005 (MC1R gene) Confidence: 0.75 | Effect size: 1.3 | Tier: Emerging

A low-penetrance variant contributing to fair skin phenotype. Less impactful than its high-confidence MC1R relatives (like rs1805007 at 0.93 confidence and 2.5 effect size). It contributes, but it’s one piece of a larger puzzle.

Low-confidence findings

rs4475691 (CLOCK gene) Confidence: 0.70 | Effect size: 1.1 | Tier: Emerging

Associated with chronotype and circadian rhythm. The effect size of 1.1 means this variant barely moves the needle. Studies exist, but replication is limited and the biological pathway is loosely defined. A typical binary report might flag this the same way it flags Factor V Leiden. That’s a problem.

rs1387923 (BDNF region) Confidence: 0.68 | Effect size: 1.2 | Tier: Emerging

A variant affecting BDNF regulation through an antisense RNA mechanism. It’s been identified in GWAS for neuroticism and mental health traits, but the functional significance is still being worked out. Filing this under “interesting but preliminary” is the honest thing to do.

rs2066702 (CBS gene) Confidence: 0.68 | Effect size: 1.2 | Tier: Emerging

May modulate homocysteine levels in combination with MTHFR variants. The keyword there is “may.” Studies are limited, and the independent contribution of this variant is unclear. Presenting it with the same authority as Factor V Leiden would be irresponsible.

Why this matters for you

When you look at a genetic health report, you’re making decisions. Maybe you’ll change your diet. Maybe you’ll ask your doctor about a screening test. Maybe you’ll worry about something for years.

Those decisions should be proportional to the evidence. A high-confidence, high-effect finding like Factor V Leiden (confidence 0.97, effect size 3.5) deserves a different response than a speculative circadian rhythm association (confidence 0.70, effect size 1.1). But if both show up as the same colored badge on a report, how would you know?

You wouldn’t. And that’s the core issue.

Genetic health reports aren’t wrong to include emerging findings. New research is valuable, and sometimes today’s preliminary association becomes tomorrow’s clinical guideline. The problem is presenting everything at the same confidence level, as if the evidence behind each finding is interchangeable.

How SoDNAscan handles this differently

Every insight in your SoDNAscan health book is scored by evidence strength. You’ll see the confidence level, the effect size, and the evidence tier for each genetic variant we analyze.

Our reference database tracks 256 SNPs across 10 biological systems, from cardiovascular and metabolic health to pharmacogenomics and neurological function. Each entry is sourced from peer-reviewed databases (ClinVar, PharmGKB, CPIC, GWAS Catalog, SNPedia) and categorized by the quality of evidence behind it.

High-confidence findings get the attention they deserve. Emerging findings are presented honestly, with appropriate context about what’s known and what’s still uncertain. You’ll never mistake a preliminary association for an established clinical finding.

Because the point of a genetic health report isn’t to give you more information. It’s to give you better information, the kind you can actually act on.

Your raw DNA file contains hundreds of thousands of data points. What matters is knowing which ones to take seriously.

SoDNAscan provides wellness-oriented genetic information for educational purposes. It does not diagnose, treat, or prevent any disease. Always consult a qualified healthcare provider before making medical decisions based on genetic information.

The Confidence Problem: Why Most Genetic Health Reports Oversimplify